Drug Profile
CTX 102
Alternative Names: CTX 103; CTX-102; Mical (2); Mical 2Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Nuvo Research
- Class Antipsoriatics; Corticosteroids; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Skin-disorders in Canada (Topical)
- 16 Mar 2021 Crescita Therapeutics has patent protection for CTX 102 in USA
- 17 Feb 2020 Phase-I clinical trials in Skin disorders in Canada (Topical) (Crescita Therapeutics pipeline, February 2020)